Dexcom (Nadsaq:DXCM) announced today that it released a new AI-powered photo meal logging feature for its Stelo platform. Stelo, the first FDA-cleared over-the-counter glucose biosensor, joins the G7 continuous glucose monitor (CGM) in offering this new feature. Smart Food Logging encourages and enables users to log meals more consistently through the use of just a […]
Dexcom
Dexcom updates CGM receiver recall that led to serious adverse events
Dexcom (Nasdaq:DXCM) has issued an update related to a recall for its continuous glucose monitor (CGM) components. Last month, the FDA disclosed Dexcom’s recalls related to its Dexcom One and One+ offerings and the G6 and G7 CGMs. The One and One+ systems, which are mainly the company’s commercial CGM offering outside the U.S., feature the established G6 and G7 sensors […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Dexcom continues advances in AI for CGM, type 2 diabetes awareness
As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and […]
Dexcom shares U.S. report on CGM benefits for type 2 diabetes
Dexcom (Nasdaq:DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S. The company released its report — “Dexcom State of Type 2 Report: Access and Attitudes Across the United States” — ahead of the American Diabetes Association’s 85th Scientific Sessions in Chicago. Findings provide insights into perceptions around […]
Dexcom has a Class I CGM receiver recall
The FDA’s recall database today posted notices related to a Class I recall for continuous glucose monitor (CGM) components made by Dexcom (Nasdaq:DXCM). Dexcom’s recalls relate to its Dexcom One and One+ offerings and the G6 and G7 CGMs. The One and One+ systems, which are mainly the company’s commercial CGM offering outside the U.S., feature […]
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
Insulet (Nasdaq:PODD) today announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It […]
Dexcom promotes Jake Leach to president role
Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO. Leach originally took over as COO in 2022. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments. […]
Dexcom expands Oura partnership with Stelo integration
Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with Stelo. Stelo, the company’s FDA-cleared over-the-counter (OTC) glucose biosensor, now gives users 24/7 glucose insights via the Oura app. Oura’s new in-app metabolic health feature, Glucose, now gives Oura members a deeper understanding of how dietary choices impact health. […]
Analysts are high on Dexcom after Q1 results, $750M repurchase program
Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus forecast. Shares of DXCM ticked up 3% to $72.30 apiece in post-market trading on Thursday. However, before hours on Friday, shares fell 1.6% to $70.26 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported profits of […]
